142 related articles for article (PubMed ID: 34628794)
1. Immunohistochemical expression of Olig2, CD99, and EMA to differentiate oligodendroglial-like neoplasms.
Kurdi M; Eberhart C
Folia Neuropathol; 2021; 59(3):284-290. PubMed ID: 34628794
[TBL] [Abstract][Full Text] [Related]
2. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
[TBL] [Abstract][Full Text] [Related]
3. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
Preusser M; Budka H; Rössler K; Hainfellner JA
Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of CD99 and EMA expression in ependymomas.
Mahfouz S; Aziz AA; Gabal SM; el-Sheikh S
Medscape J Med; 2008 Feb; 10(2):41. PubMed ID: 18382710
[TBL] [Abstract][Full Text] [Related]
5. SOX10 and Olig2 as negative markers for the diagnosis of ependymomas: An immunohistochemical study of 98 glial tumors.
Švajdler M; Rychlý B; Mezencev R; Fröhlichová L; Bednárová A; Pataky F; Daum O
Histol Histopathol; 2016 Jan; 31(1):95-102. PubMed ID: 26287936
[TBL] [Abstract][Full Text] [Related]
6. Olig2 is useful in the differential diagnosis of oligodendrogliomas and extraventricular neurocytomas.
Okada M; Yano H; Hirose Y; Nakayama N; Ohe N; Shinoda J; Iwama T
Brain Tumor Pathol; 2011 Apr; 28(2):157-61. PubMed ID: 21312066
[TBL] [Abstract][Full Text] [Related]
7. Central neurocytoma with ependymoma-like glial component.
Kawakami F; Nambu J; Hirose T; Sasayama T; Itoh T
Brain Tumor Pathol; 2015 Apr; 32(2):119-23. PubMed ID: 25348672
[TBL] [Abstract][Full Text] [Related]
8. Can oligodendrocyte transcriptional factor-2 (Olig2) be used as an alternative for 1p/19q co-deletions to distinguish oligodendrogliomas from other glial neoplasms?
Kurdi M; Alkhatabi H; Butt N; Albayjani H; Aljhdali H; Mohamed F; Alsinani T; Baeesa S; Almuhaini E; Al-Ghafari A; Hakamy S; Faizo E; Bahakeem B
Folia Neuropathol; 2021; 59(4):350-358. PubMed ID: 35114775
[TBL] [Abstract][Full Text] [Related]
9. CD99 immunoreactivity in ependymoma.
Choi YL; Chi JG; Suh YL
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):125-9. PubMed ID: 11396629
[TBL] [Abstract][Full Text] [Related]
10. Value and limits of immunohistochemistry in differential diagnosis of clear cell primary brain tumors.
Koperek O; Gelpi E; Birner P; Haberler C; Budka H; Hainfellner JA
Acta Neuropathol; 2004 Jul; 108(1):24-30. PubMed ID: 15108012
[TBL] [Abstract][Full Text] [Related]
11. A Comparative Immunohistochemical Study of Epithelial Membrane Antigen and NHERF1/EBP50 in the Diagnosis of Ependymomas.
Nambirajan A; Sharma MC; Rajeshwari M; Kakkar A; Suri V; Sarkar C
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):71-78. PubMed ID: 27753657
[TBL] [Abstract][Full Text] [Related]
12. Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors.
Fujisawa H; Marukawa K; Hasegawa M; Tohma Y; Hayashi Y; Uchiyama N; Tachibana O; Yamashita J
J Neurosurg; 2002 Dec; 97(6):1350-5. PubMed ID: 12507133
[TBL] [Abstract][Full Text] [Related]
13. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
14. OLIG2 immunolabeling in feline ependymoma.
Demeter EA; Kent M; Glass EN; Rissi DR; Edwards J; Miller AD
J Vet Diagn Invest; 2022 Sep; 34(5):898-901. PubMed ID: 35762120
[TBL] [Abstract][Full Text] [Related]
15. Primary intraventricular oligodendroglioma: A case report of the usefulness of Olig2 immunohistochemistry for diagnosis.
Matsumoto H; Yoshida Y
Neuropathology; 2015 Dec; 35(6):553-60. PubMed ID: 26079719
[TBL] [Abstract][Full Text] [Related]
16. Intraoperative imprint cytology of central neurocytoma: The great oligodendroglioma mimicker.
Klysik M; Gavito J; Boman D; Miranda RN; Hanbali F; De Las Casas LE
Diagn Cytopathol; 2010 Mar; 38(3):202-7. PubMed ID: 19795492
[TBL] [Abstract][Full Text] [Related]
17. Light microscopic demonstration of the microlumen of ependymoma: a study of the usefulness of antigen retrieval for epithelial membrane antigen (EMA) immunostaining.
Kawano N; Yasui Y; Utsuki S; Oka H; Fujii K; Yamashina S
Brain Tumor Pathol; 2004; 21(1):17-21. PubMed ID: 15696964
[TBL] [Abstract][Full Text] [Related]
18. Central neurocytoma: clinico-pathological study of 5 cases and review of the literature.
Maiuri F; Spaziante R; De Caro ML; Cappabianca P; Giamundo A; Iaconetta G
Clin Neurol Neurosurg; 1995 Aug; 97(3):219-28. PubMed ID: 7586853
[TBL] [Abstract][Full Text] [Related]
19. Neuronal nuclear antigen (NeuN): a new tool in the diagnosis of central neurocytoma.
Soylemezoglu F; Onder S; Tezel GG; Berker M
Pathol Res Pract; 2003; 199(7):463-8. PubMed ID: 14521262
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas.
Hasselblatt M; Paulus W
Acta Neuropathol; 2003 Oct; 106(4):385-8. PubMed ID: 12898159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
